Blockage of MLKL prevents myelin damage in experimental diabetic neuropathy

Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2121552119. doi: 10.1073/pnas.2121552119. Epub 2022 Mar 28.

Abstract

SignificanceDiabetic neuropathy is a commonly occurring complication of diabetes that affects hundreds of millions of patients worldwide. Patients suffering from diabetic neuropathy experience abnormal sensations and have damage in their peripheral nerve axons as well as myelin, a tightly packed Schwann cell sheath that wraps around axons to provide insulation and increases electrical conductivity along the nerve fibers. The molecular events underlying myelin damage in diabetic neuropathy are largely unknown, and there is no efficacious treatment for the disease. The current study, using a diabetic mouse model and human patient nerve samples, uncovered a molecular mechanism underlying myelin sheath damage in diabetic neuropathy and provides a potential treatment strategy for the disease.

Keywords: MLKL; diabetic neuropathy; myelin.

MeSH terms

  • Animals
  • Axons
  • Diabetes Mellitus*
  • Diabetic Neuropathies* / etiology
  • Diabetic Neuropathies* / prevention & control
  • Humans
  • Mice
  • Myelin Sheath
  • Peripheral Nerves
  • Protein Kinases
  • Schwann Cells / physiology

Substances

  • MLKL protein, human
  • MLKL protein, mouse
  • Protein Kinases